If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.
Accepts Healthy Volunteers:
- Diagnosis of PNH by flow cytometry
- Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus a documented LDH level ≥ 1.5 x the upper limit of normal (ULN) and/or the presence of a known C5 mutation conferring resistance to eculizumab
- History of meningococcal disease
- Current systemic infection or suspicion of active bacterial infection